Overheard on Social Media: CURE Readers Discuss Survivorship Plans

CURE’s Clinical Trial Corner: November 2020

FDA Accelerates Approval of Danyelza for Children and Adults with Relapsed or Refractory High-Risk Neuroblastoma

First-Line Treatment with Additional Combination Therapy After Resection May Improve Survival for Pancreatic Cancer

Keytruda With an Androgen Receptor Modulator May Produce a Modest Benefit in Women with Androgen Receptor-Positive, Triple-Negative Breast Cancer